Parental administration of antipyretics to children with upper respiratory tract infections without consultation with a physician by Andabaka, Tea et al.
48
www.cmj.hr
Aim To evaluate the administration of antipyretics to chil-
dren with upper respiratory tract infections (URTI) by their 
parents or guardians without consultation with physicians, 
and compare epidemiological and clinical characteristics 
of patients who received antipyretics and of untreated pa-
tients.
Methods  A  prospective  observational  study  was  per-
formed in three pediatric clinics in Zagreb, Croatia, from 
March to June 2002. A total of 171 children aged from 2 
to 14 years with symptoms and signs of URTI lasting more 
than 2 days and fever above 38°C lasting more than 2 days 
were included in the study. Data were collected on the us-
age of antipyretics, patients’ demographic and epidemio-
logical characteristics, and clinical signs and symptoms.
Results  Antipyretics,  predominantly  paracetamol,  were 
used in 29.8% of patients. Their usage was less frequent in 
children attending day-care centers (49% of treated and 
70% of untreated children, P = 0.014) and in children with 
reiterated URTIs (33.3% of treated and 55.8% of untreated 
children, P = 0.008). However, it was more frequent in chil-
dren with recent URTIs in the family (33.3% of treated and 
7.5% of untreated children, P < 0.001). Overall, most clinical 
signs and symptoms of URTI were notably less pronounced 
in patients treated with antipyretics.
Conclusions  Antipyretics  use  correlated  with  less  pro-
nounced clinical signs and symptoms of infection, which 
indicates  their  anti-inflammatory  activity,  but  also  with 
negative effects such as lethargy. It is necessary to educate 
parents on the positive and negative aspects of antipyret-
ics use and on the optimal choice of an antipyretic drug. Received: September 29, 2010
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Infections of the upper respiratory tract (URTI) are associated 
with some of the most common infectious diseases, like phar-
yngitis, rhinitis, sinusitis, and otitis media, which account for 
millions of visits to physicians annually. URTIs, mostly caused 
by respiratory viruses, are the most frequent illnesses in child-
hood, often characterized by a rapid onset of fever (1).
Fever can enhance host resistance to infection, and inter-
ventions to reduce fever may negatively affect the out-
come of the illness (2-4). Additionally, fever is, particular-
ly in children, associated with irritability, stress, and high 
parental anxiety. Parental fear about the presumed harm-
ful effects of fever in children (also called “fever phobia”) is 
still common, and in most cases is caused by misconcep-
tions (5). Most caregivers and many clinicians erroneously 
believe that treatment of fever will relieve symptoms and 
prevent harmful effects such as febrile convulsions (6).
The drugs most commonly used for treating fever are par-
acetamol  (acetaminophen),  aspirin  (acetylsalicylic  acid), 
and ibuprofen (7). As antipyretic drugs, paracetamol and 
ibuprofen are also approved for treating fever in children. 
Current World Health Organization guidelines on the man-
agement of fever recommend the use of paracetamol for 
treating  children  with  fever  ≥39°C  (8).  However,  recent 
studies show that the excessive use of paracetamol might 
be associated with greater morbidity (asthma, allergic rhin-
itis, and eczema) (9-12).
URTIs are the most common reason for the administration 
of antipyretics to children, which is often done without su-
pervision of a physician (13).
Our research was performed as a part of a larger clinical 
study that investigated the role of a multiplex polymerase 
chain reaction method for the detection of respiratory bac-
teria in children with URTI (14). The aim of our research was 
to assess the administration of antipyretics to children with 
URTIs by their parents or guardians and without consul-
tation with physicians, and to compare the demograph-
ic, epidemiological, and clinical characteristics in patients 
who received antipyretics and those who did not.
PATiEnTS AnD mEThoDS
This research was done as a part of a larger prospective 
observational  clinical  study  on  the  role  and  prevalence 
of  Streptococcus  pneumoniae,  Moraxella  catarrhalis,  He-
mophylus  influenzae,  Chlamydia  pneumonia,  and  Myco-
plasma pneumoniae in children with URTI. The study was 
performed by 8 attending physicians at 3 sites in Zagreb 
(University  Pediatric  Hospital  Zagreb,  Dr  Fran  Mihaljević 
University  Hospital  for  Infectious  Diseases,  and  Primary 
Care Health Center Trnje) in accordance with the ethical 
standards set by the institutional Ethics Committees. We 
planned to include a sample of 200 children, in order to es-
timate the incidence of atypical pathogens. Each physician 
was provided with customized forms for entering data on 
the children eligible for inclusion into the study.
Children eligible for inclusion were those aged 2 to 14 years, 
with symptoms and signs consistent with URTI lasting for 
more than 2 days, fever above 38°C lasting for more than 2 
days, no antibiotic treatment received, and informed con-
sent signed by their parents or guardians. The same child 
could not have participated in the study twice during the 
period of enrollment, from March to June 2002. All the pa-
tients included in hospitals were treated as outpatients and 
did not differ in the intensity of symptoms from the patients 
included in the study at the primary care health center.
For each participant, we collected demographic and epi-
demiological data (sex, age, body weight and height and 
data on attendance of school or day-care centers, siblings, 
family history of URTI, prior episodes of URTI, chronic dis-
eases, allergies, concomitant medications, and duration of 
symptoms), bacteriological findings, and clinical character-
istics of URTI (sudden or gradual onset of disease, presence 
of non-specific findings like lethargy, irritability, anorexia, 
vomiting, chills and headache, cough, nose obstruction, 
quality of nasal discharge, ear pain, ear drainage, presence 
of ear fluid, middle ear effusion, hyperemic or transpar-
ent tympanic membrane, enlarged cervical lymph nodes, 
throat erythema, throat exudates, and throat edema). The 
attending physician recorded the presence or absence of 
specific and non-specific clinical findings in every child.
During the first visit, parents were asked whether they had 
administered any medication to their child for the current ep-
isode of URTI before visiting the physician. They were asked 
to provide data on the type of drug, route of administration, 
dose, and reason for usage. Patients were divided into two 
groups: the group that had received any dose of antipyretics 
and the group that had not received antipyretics for the cur-
rent URTI episode before they visited a physician.
Statistical analysis
The collected data were entered into a database that 
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Softleks DDE (Softleks d.o.o., Zagreb, Croatia). All data were 
entered twice and all discrepancies were resolved by ex-
amining the original data collection forms. For the purpose 
of logistic regression analysis and in order to maintain the 
power of this research, some missing values were imput-
ed. This imputation was based on the variables clinically 
related to the variable with the missing values. Where such 
practice was not possible, a missing value was replaced 
with “no,” based on the presumption that physicians would 
omit the parameter’s value if the characteristics were not 
present. The missing continuous variables were imputed 
by median values. Bivariate analysis did not include the im-
puted values (15).
Results of univariate analysis were expressed as median 
and interquartile range (25th-75th percentile) for continu-
ous variables and as frequencies and percents for categori-
cal variables. Bivariate analysis, used for comparing the two 
groups, was performed using the Wilcoxon test for contin-
uous variables, χ2 test for categorical variables, and Fisher 
exact test when appropriate. Logistic regression analysis 
was performed to identify independent factors associated 
with the use of antipyretics as self-administered medica-
tion. Variables that differed between the two groups in bi-
variate analysis (P < 0.050) were included into the model. 
The assessment of the fit of the statistical model was done 
by the Hosmer-Lemeshow goodness-of-fit test. All P values 
are two-tailed, with the significance level set at 0.05. All the 
analyses were performed using the SAS 9.1 statistical soft-
ware (SAS Institute Inc., Cary, NC, USA).
RESulTS
The study population consisted of 172 patients. For one 
child, no written information was available, so the data 
were analyzed for 171 children who were included in the 
study based on the inclusion and exclusion criteria. The 
planned study population of 200 children was not reached 
due to the low frequency of infections in the study period.
Before the inclusion into the study, 56 children (32.8%) had 
received medication for the symptomatic treatment of a 
URTI episode without physician’s supervision. Most com-
monly administered drugs were antipyretics, used in 51 
patients (29.8%). Forty-two patients were given paraceta-
mol orally (24.6%), 5 were given acetylsalicylic acid (2.9%), 
and 7 nonsteroidal anti-inflammatory drugs (4.1%) (Table 
1). For the purpose of all further analyses, patients were 
divided into two groups: one group that had received 
antipyretics (51 patients) and the other that had not 
(120 patients). Since the data on the administered anti-
pyretic drugs dosage were not reliably collected, they were 
not used in the analyses. Other drugs taken as symptom-
atic treatment were butamirate applied orally in 4 children 
TABlE 1. Parental administration of medication to children 
with symptoms of upper respiratory tract infections (uRTi) 
before visiting a physician
medication
no. (%) of 
patients
Any therapy for symptomatic treatment of uRTi 56 (32.8)
Antipyretic drugs: 51 (29.8)
only paracetamol 39 (22.8)
only acetylsalicylic acid   5 (2.9)
only non-steroid anti-inflammatory drugs   4 (2.3)
combined (paracetamol + ibuprofen and/or 
diclofenac)
  3 (1.8)
TABlE 2. Comparison of demographic and epidemiologic data 
on patients who did and did not receive antipyretic drugs for 
the upper respiratory tract infection (uRTi) before visiting a 
physician
no. (%) of patients
Characteristic
treated with 
antipyretics 
(n = 51)
not treated with 
antipyretics 
(n = 120) P
Age, years, median 
(range)
  6.0 (3.0-9.0)   5.0 (3.5-7.0)   0.360*
Age group:
2-3 y 13 (25.5) 27 (22.5)   0.457†
3.1-6.9 y 19 (37.3) 57 (47.5)
≥7 y 19 (37.3) 36 (30.0)
Sex:
male 27 (52.9) 70 (58.3)   0.613‡
female 24 (47.1) 50 (41.7)
Chronic diseases   2 (3.9)   6 (5.0)   1.000‡
Allergies   7 (13.7)   5 (4.2)   0.044‡
Attending day-care 
center
25 (49.0) 84 (70.0)   0.014‡
Attending school 19 (37.3) 35 (29.2)§   0.369‡
having siblings 30 (58.8)§ 79 (65.8)   0.391‡
having sister(s) 16 (31.4) 60 (50.0)   0.029‡
having brother(s) 18 (35.3) 41 (34.2)   0.999‡
Recent uRTi in family 17 (33.3)§   9 (7.5) <0.001‡
Frequent uRTi 17 (33.3) 67 (55.8)   0.008‡
Sudden onset of uRTi 
episode
27 (52.9) 60 (50.0)   0.741‡
Duration of symptoms, 
days, median (range)
  3.0 (2.0-4.0)   3  .0 (3.0-3.0)II   0.275*
*Wilcoxon test.
†χ2 test.
‡Fisher exact test.
§Data missing for 1 patient.
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(2.3%) to alleviate cough and loratadin in 2 patients (1.2%) 
as an antihistaminic drug. Tobramycin was administered 
topically to one patient. As the systemic effect of antibiot-
ics is not to be expected after the topical administration, 
the data on this patient were retained in the analysis.
The  majority  of  patients  were  preschool  children  (Table 
2). Eight of 171 patients reported that they suffered from 
chronic diseases (eg, asthma, epilepsy, bronchitis, etc.), and 
2 of them were regularly taking concomitant medications. 
A higher incidence of allergies was reported in the group 
of patients who had received antipyretics (Table 2). Out of 
12 patients in whom allergy was reported, 8 reported using 
agents causing allergy. Three children were allergic to peni-
cillin, 2 to dust, 2 to pollens, and 1 to feathers and birch.
Attendance of a day-care center increased the risk of fre-
quent episodes of URTI (odds ratio [OR], 2.67; 95% con-
fidence  interval  [CI],  1.40-5.12).  Children  who  attended 
day-care centers (P = 0.005) and those who had frequent 
URTIs (P = 0.008), defined as at least 3 episodes of URTI in 6 
months preceding the enrollment, were given antipyretics 
less frequently (Table 2). On the other hand, children with 
a recent URTI episode in the family were given antipyretics 
more frequently (Table 2).
Multivariate logistic regression analysis was performed to 
determine the epidemiologic factors that have the great-
est influence on the parental tendency to administer anti-
pyretics to their children. Three explanatory variables en-
tered the model: attendance of day-care centers, frequent 
episodes of URTI, and a recent URTI in the family. Multivari-
ate analysis showed that the history of frequent URTI in the 
child was associated with not using antipyretics (OR, 2.13; 
95% CI, 1.02-4.48), while a recent URTI in the family signifi-
cantly increased the probability of using antipyretics (OR, 
5.82; 95% CI, 2.32-14.61).
In order to observe the differences in the clinical presenta-
tion of URTI, we compared the symptoms and signs of UR-
TIs in two groups of patients. Patients who had not received 
antipyretics more frequently experienced irritability, vomit-
ing, chills, headache, nasal speech, and cough (Table 3). Pa-
tients who had received antipyretics more frequently expe-
rienced lethargy, defined as daytime sleepiness (P = 0.029). 
Patients who had not received antipyretics more frequently 
experienced most clinical signs of respiratory infection (na-
sal obstruction, nasal discharge, non-transparent tympanic 
membrane, severe throat erythema, throat exudates, uvular 
edema and purulent exudates on tonsils) (Table 3). On the 
TABlE 3. Comparison of clinical signs and symptoms of upper 
respiratory tract infection (uRTi) in patients who did and did 
not receive antipyretic drugs before visiting a physician
no. (%) of patients
Symptom or sign
treated with 
antipyretics 
(n = 51)
not treated with 
antipyretics 
(n = 120) P
lethargy 12 (23.5)   12 (10.0)†   0.029*
irritability 27 (52.9)   85 (70.8)   0.034*
Anorexia 40 (78.4)   79 (65.8)   0.145*
Vomiting 11 (21.6)   46 (38.6)   0.035*
Chills   9 (17.6)   56 (46.7) <0.001*
headache 30 (58.8)   91 (75.8)   0.029*
nasal speech 27 (52.9)† 100 (95.8)   0.006*
nasopharyngeal 
irritation
42 (82.4)† 115 (90.8)   1.000*
Cough 32 (62.8)   95 (79.2)   0.035*
Ear pain   8 (15.7)   35 (29.2)   0.083*
hearing loss  0   0 ‡
Enlarged cervical lymph 
nodes
32 (62.8)   77 (64.2)   0.864*
nasal obstruction 31 (60.8)   98 (81.7)§   0.006*
nasal discharge: 29 (56.9) 111 (92.5) <0.001*
serous 11 (21.6)   51 (42.5)   0.010*
seromucous 17 (33.3)   47 (39.2)   0.495*
mucopurulent   2 (3.9)   18 (15.0)   0.040*
Ear drainage  0     1 (0.8)†   1.000*
Presence of fluid   3 (5.9)   0 §   0.020*
hyperemic tympanic 
membrane
11 (21.6)   23 (19.2)†   0.834*
Transparent tympanic 
membrane
38 (74.5)   39 (32.5)† <0.001*
middle ear effusion   3 (5.9)     1 (0.8)II   0.080*
Erythema of the throat: 51 (100) 112 (93.3)   0.999*
absent   0 (3.6)     8 (6.7)
mild 10 (19.6)   35 (29.2)
moderate 37 (72.6)   60 (50.0)
severe   4 (7.8)   17 (14.2)
Exudate in the throat: 19 (37.3)   81 (67.5) <0.001*
seromucous 13 (68.4)   65 (80.2)
mucopurulent   6 (31.6)   16 (19.8)   0.263*
uvular edema   7 (13.7)   82 (68.3) <0.001*
Pharyngeal edema 44 (86.3)   78 (65.0)§   0.005*
Palatal edema 28 (54.9)   61 (50.8)†   0.738*
Tonsils out of palatal 
arches
37 (72.6)†   67 (55.8)†   0.059*
Swollen tonsils 38 (74.5)†   70 (58.3)   0.057*
Purulent exudates on 
tonsils
  5 (9.8)†   42 (35.0)† <0.001*
*Fisher exact test.
†Data missing for 1 patient.
‡Data missing for 9 patients.
§Data missing for 2 patients.
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other hand, patients who had received antipyretics more 
frequently experienced ear fluid and pharyngeal edema 
(P = 0.020 and P = 0.005, respectively).
The connection between the use of antipyretics and the 
incidence of symptoms and signs of infection was evalu-
ated by a multivariate analysis. In order to assess the fac-
tors independently associated with the use of antipyret-
ics, two models were formed. The first model included 6 
explanatory variables representing symptoms of URTIs: ir-
ritability, lethargy, vomiting, chills, headache, and cough. 
Multicollinearity was not observed. There were no suspect-
ed interactions. The model fitted well (Hosmer-Lemeshow 
goodness-of-fit test: χ2 = 11.43, P = 0.671). Likelihood-ratio 
test did not confirm the global null hypothesis (P < 0.001). 
The use of antipyretics was independently associated with 
more than three times higher incidence of lethargy (OR, 
3.37; 95% CI, 1.25-9.13) and inversely associated with the 
presence of chills (OR, 0.36; 95% CI, 0.15-0.91). The second 
model included 4 explanatory variables representing clini-
cal signs on physical examination: presence of nasal dis-
charge,  presence  of  completely  transparent  tympanic 
membrane, presence of throat exudates, and pharyngeal 
edema. Uvular edema and purulent exudates on tonsils 
were omitted from the model because of the small num-
ber of patients with positive findings. Multicollinearity was 
not observed. There were no suspected interactions. The 
model fitted well (Hosmer-Lemeshow goodness-of-fit test: 
χ2 = 5.12, P = 0.644). Likelihood-ratio test did not confirm 
the global null hypothesis (P < 0.001). The presence of nor-
mal, transparent tympanic membrane on otoscopy was 
distinctly more common in children who had received an-
tipyretics (OR, 5.50; 95% CI, 2.31-13.10), as was the absence 
of nasal discharge and throat exudates (inverse association 
between antipyretics use and nasal discharge/throat exu-
dates, OR, 0.10; 95% CI, 0.04-0.29 and OR, 0.40; 95% CI, 0.17-
0.90, respectively). On the other hand, the occurrence of 
pharyngeal edema was more than three times more com-
mon in patients who had received antipyretics (OR, 3.43; 
95% CI, 1.24-9.45).
DiSCuSSion
Our  observational  study  showed  that  parents  adminis-
tered antipyretics to their children with acute URTI without 
consultation with physicians in less than one third of cas-
es. These results are compatible with previous reports (5). 
The reasons why parents restrain the children’s intake of 
antipyretics were not further evaluated. The most com-
monly  administered  antipyretic  was  paracetamol, 
applied orally. Combined paracetamol plus ibuprofen ther-
apy was administered in fewer than 2% of patients, which 
is in accordance with the recent guidelines (16). Almost 3% 
of parents administered aspirin, which indicates a lack of 
awareness of the potential hazard associated with the use 
of acetylsalicylic acid (17).
Even though patients who had received antipyretics had a 
higher incidence of allergies, this can hardly be associated 
with antipyretics use, because it was only recorded during 
an actual episode of URTI. It can only be assumed that the 
parent, who decided to administer antipyretics to the child 
during our study, had also been giving antipyretics regu-
larly to his child during URTI episodes.
Our study showed that the parents’ tendency to adminis-
ter antipyretics to their children was related to the history 
of frequent URTIs in their children and to day-care center 
attendance. Almost half of the patients registered for the 
study had a history of frequent URTI episodes, while almost 
two thirds were regularly attending day-care centers. Chil-
dren attending day-care centers were shown to be at a 
higher risk of acquiring frequent URTIs (18) and were less 
likely to receive antipyretics. This finding suggests that pre-
vious experience of self-limiting illness leads to a lower con-
sumption of antipyretics. It is also possible that parents of 
these children with time become reluctant to use antipyret-
ics. In contrast, children with a recent case of URTI in their 
family received antipyretics more often. This might be re-
lated to their easy availability and storing of unused drugs 
in the household. However, these results are inconclusive 
because of the small number of patients with a history of a 
recent URTI in the family. Low exposure to URTI in the family 
also implies that the acquisition of URTI at home is rare.
Our study showed that the use of antipyretics correlated 
with the less pronounced group of clinical signs and symp-
toms of respiratory infection, which implies the drugs’ an-
ti-inflammatory activity. However, antipyretics use was also 
associated with a greater incidence of lethargy, suggesting 
that antipyretics could cause certain unfavorable outcomes. 
However, lethargy might be the consequence of prior irri-
tability and lack of sleep in the initial phase of the disease. 
Other drugs which might cause lethargy were not concom-
itantly used. Besides this, our results should be taken with 
caution since a study of this design cannot prove the causal 
relationship between the use of antipyretics and lethargy.
The primary indicators of the reduced intensity of inflam-
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ent tympanic membrane and absence of nasal discharge 
and throat exudates. Visible changes on the tympanic 
membrane were more than five times less common in 
patients receiving antipyretics, probably due to the re-
duction in the signs of inflammation. Pharyngeal edema, 
on the other hand, occurred more often in patients tak-
ing antipyretics. However, these results are inconclusive 
due to the low small number of patients with such symp-
toms.
Overall, the lower presence and intensity of clinical signs 
could hardly be attributed to the activity of nonsteroidal 
anti-inflammatory  drugs  or  acetylsalicylic  acid,  because 
these drugs had been given to less than a quarter of pa-
tients treated with antipyretics. Reduction in signs of in-
flammation  was  most  probably  caused  by  paracetamol 
use, even though a Cochrane review reported inconsistent 
and weak evidence to support this view (19).
Our study has several limitations. This was an explorato-
ry analysis that was not predefined by the protocol. Ad-
ditional parameters, which would help interpret the ob-
served differences in the two groups of patients, were 
not investigated, and a selection bias is present. Anoth-
er drawback is that we did not properly collect the data 
on the dosages of antipyretics administered to children. 
It was unclear whether the values in the collection forms 
were daily or total amounts, and therefore these data had 
to be omitted from the analyses. For the purpose of logis-
tic regression analysis, some missing values were imput-
ed. Since the number of missing values is relatively small, 
imputation did not significantly change the results. Not-
withstanding these limitations, our study undoubtedly in-
dicates some beneficial effects of paracetamol use, which 
cannot easily be diminished by some potentially negative 
long term effects like the incidence of asthma and aller-
gies (9-12). However, the controversies regarding the use 
of paracetamol in children remain, and further studies are 
needed to investigate these (19).
Our study revealed different parents’ approaches to the 
use of antipyretics, probably based on previous experience 
and misconceptions, and not on medical facts. Therefore, 
it  is  necessary  to  educate  parents  about  both  positive 
and negative aspects of antipyretics use and the optimal 
choice of an antipyretic drug. Parents should always weigh 
both beneficial and possible long term detrimental effects 
before administering antipyretics to their children. Recent 
guidelines recommend the use of antipyretics in children 
only when fever is associated with evident discomfort (20). 
High use of antipyretics makes further studies on this topic 
justified and indispensable.
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